Needham & Company analyst Alan Carr weighed in on Vivus (NASDAQ: VVUS) following Q1 results which showed that while Qsymia ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE